NewBioRx produces CJC-1295 No DAC with Ipamorelin using solid-phase peptide synthesis followed by high-performance liquid chromatography purification
Establishing that it is requires a selective kinase inhibitor, a blocking antibody, a receptor-null or knockdown background, or at minimum a parallel insulin comparison, and a large amount of published and unpublished work on this compound does not include any of those
It is essential to ensure the treatment is done in a sterile, clinical environment with proper professional oversight
Administration routes include subcutaneous injection (via syringe, pen, or continuous subcutaneous insulin infusion pump), intravenous infusion (restricted to monitored clinical settings), and, more recently, inhaled insulin for prandial coverage
If health anxiety is significantly affecting your experience of GLP-1 treatment - driving frequent unplanned consultations, obsessive symptom checking, or significant distress about the medication - this is worth raising directly with your SheMed clinician and potentially your GP